Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)
Stefano Fiorucci, Michele Biagioli, Valentina Sepe, et al.
Expert Opinion on Investigational Drugs (2020) Vol. 29, Iss. 6, pp. 623-632
Closed Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 203
Bile acids and their receptors in metabolic disorders
Stefano Fiorucci, Eleonora Distrutti, Adriana Carino, et al.
Progress in Lipid Research (2021) Vol. 82, pp. 101094-101094
Closed Access | Times Cited: 175
Gut–liver axis: barriers and functional circuits
Oliver Pabst, Mathias W. Hornef, Frank G. Schaap, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 7, pp. 447-461
Closed Access | Times Cited: 166
Farnesoid X receptor (FXR): Structures and ligands
Longying Jiang, Huajun Zhang, Desheng Xiao, et al.
Computational and Structural Biotechnology Journal (2021) Vol. 19, pp. 2148-2159
Open Access | Times Cited: 152
Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases
Baoyi Guan, Jinlin Tong, Haiping Hao, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 5, pp. 2129-2149
Open Access | Times Cited: 112
Gut liver brain axis in diseases: the implications for therapeutic interventions
Mengyao Yan, Shuli Man, Benyue Sun, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 86
Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
Christoph Grander, Felix Grabherr, Herbert Tilg
Cardiovascular Research (2023) Vol. 119, Iss. 9, pp. 1787-1798
Open Access | Times Cited: 79
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
Tingying Jiao, Yuandi Ma, Xiaozhen Guo, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 5, pp. 1103-1119
Open Access | Times Cited: 77
Bile Acid Receptors and the Gut–Liver Axis in Nonalcoholic Fatty Liver Disease
Rui Xue, Lianyong Su, Shengyi Lai, et al.
Cells (2021) Vol. 10, Iss. 11, pp. 2806-2806
Open Access | Times Cited: 61
FXR: structures, biology, and drug development for NASH and fibrosis diseases
Siyu Tian, Shuming Chen, Chengxi Pan, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 5, pp. 1120-1132
Open Access | Times Cited: 43
Immunomodulatory functions of FXR
Stefano Fiorucci, Angela Zampella, Patrizia Ricci, et al.
Molecular and Cellular Endocrinology (2022) Vol. 551, pp. 111650-111650
Closed Access | Times Cited: 43
The progress of molecules and strategies for the treatment of HBV infection
Youlu Pan, Heye Xia, Yanwen He, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 23
A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development
Tang Yu-hong, Yujuan Fan, Yiming Wang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116658-116658
Open Access | Times Cited: 11
Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis
Yong‐Yu Yang, Li Xie, Ning‐Ping Zhang, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 5, pp. 1180-1190
Open Access | Times Cited: 37
Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD‐related cirrhosis
Devon Chang, Emily Truong, Edward Mena, et al.
Hepatology (2022) Vol. 77, Iss. 2, pp. 546-557
Closed Access | Times Cited: 37
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH
Silvia Marchianò, Michele Biagioli, Elva Morretta, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 21
Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD)
Ying Zhao, Yanni Zhou, Dan Wang, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17514-17514
Open Access | Times Cited: 21
Lingguizhugan decoction improves non-alcoholic steatohepatitis partially by modulating gut microbiota and correlated metabolites
Mingzhe Zhu, Xue Wang, Kai Wang, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 19
FXR and NASH: an avenue for tissue-specific regulation
Zakiyah Henry, Vik Meadows, Grace L. Guo
Hepatology Communications (2023) Vol. 7, Iss. 5
Open Access | Times Cited: 18
The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus
Monika Bhardwaj, Papiya Mitra Mazumder
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Closed Access | Times Cited: 7
Current Landscape and Evolving Therapies for Primary Biliary Cholangitis
Stefano Fiorucci, Ginevra Urbani, Cristina Di Giorgio, et al.
Cells (2024) Vol. 13, Iss. 18, pp. 1580-1580
Open Access | Times Cited: 6
Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
Weiyi Qu, Tengfei Ma, Jingjing Cai, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 40
The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease
Branka Filipović, Snežana Lukić, Dragana Mijač, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13219-13219
Open Access | Times Cited: 33
Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives
Mengyao Yan, Shuli Man, Long Ma, et al.
Metabolism (2022) Vol. 134, pp. 155264-155264
Closed Access | Times Cited: 25
Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena
Aamir Bashir, Ajay Duseja, Arka De, et al.
Liver Research (2022) Vol. 6, Iss. 2, pp. 72-83
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top